Imatinib Zydus (Imatinib Mesilate)

Imatinib mesilate blocks the ATP‑binding pocket of BCR‑ABL, KIT and PDGFRA tyrosine kinases, locking them in an inactive state. This inhibition stops downstream signaling pathways that promote malignant cell growth and survival, leading to apoptosis of the cancerous cells while largely sparing normal cells.

The specific dose of Imatinib Zydus is determined by the prescribing physician based on the patient’s diagnosis, disease stage, body weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional can set the appropriate dosing regimen.

The safety of Imatinib Zydus in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Imatinib Zydus product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and GIST. Newer agents such as dasatinib, nilotinib or ponatinib may offer activity against certain resistant mutations, but Imatinib retains a well‑characterised safety profile and is often preferred as first‑line therapy in many treatment guidelines.

Imatinib Zydus tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not store in areas of high humidity or extreme temperature fluctuations.

Imatinib Zydus is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe neutropenia or other cytopenias, hepatotoxicity with marked liver enzyme elevation, cardiac failure or reduced left‑ventricular ejection fraction, pulmonary arterial hypertension, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these events.

Imatinib Zydus is contraindicated in patients with known hypersensitivity to imatinib mesilate or any of the tablet excipients. Caution is also advised for individuals with pre‑existing severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant unless the therapeutic benefit justifies the potential risk.